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Gangliosides are sialylated membrane glycosphingolipids especially abundant in mammalian brain tis-sue. Sialic acid O-acetylation is one of 
the most common structural modiﬁcations of gangliosides which considerably inﬂuences their chemical properties. In this study, 
gangliosides extracted from brain tissue of mice with altered ganglioside biosynthesis (St8sia1 null and B4galnt1 null mice) were structurally 
characterized and their acetylation pattern was analyzed. Extracted native and alkali-treated gangliosides were resolved by high performance 
thin layer chromatography. Ganglioside mixtures as well as separated individual ganglioside fractions were further analyzed by tandem mass 
spectrometry. Several O-acetylated brain ganglioside species were found in knockout mice, not present in the wild-type mice. To the 
our knowledge this is the ﬁrst report on the presence of O-acetylated GD1a in St8sia1 null mice and O-acetylated GM3 species in B4
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as well needed in order to explore the effects of acetylation on ganglioside interactions with other molecules and consequently the physiological role 
of acetylated ganglioside species.
1. Introduction
Gangliosides are complex sialylated glycosphingolipids espe-
cially abundant and structurally diverse in mammalian nervous
system.1 Gangliosides are anchored with their ceramide moiety
in the outer leaﬂet of the plasma membrane, while the carbohy-
in multitude of processes including signaling events, apoptosis,
proliferation, neurotransmitter positioning, pathogen binding,
etc.2,3,5–9 It has been shown that speciﬁc brain ganglioside species
participate in neuron–glia interactions, for example GD1a and
GT1b are ligands for myelin-associated glycoprotein (MAG).10
Therefore, shared effect of changes in ganglioside composition,
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ganglioside modiﬁcations, and presence/absence of speciﬁc gangli-
oside species may lead to alterations in cell metabolism.11–15
Studies using genetically modiﬁed mouse models with dis-
rupted ganglioside biosynthetic pathway have greatly contributed
to the present body of knowledge on speciﬁc ganglioside roles.16,17
Ganglioside synthesis includes a stepwise action of different glyco-
syl and sialyl transferases9,18,19 (Fig. 1). Mice with changed gangli-
oside composition were generated by selectively knocking out
speciﬁc biosynthetic enzymes of that pathway, for example, St8sia1
null mice lack the enzyme GD3 synthase (EC 2.4.99.8) with conse-
quent deﬁciency in b- and c-series gangliosides, while B4galnt1 null
mice lack all complex gangliosides accumulating just GM3 and
GD3 due to deﬁciency in GM2/GD2 synthase (EC 2.4.1.92). Pheno-
type of these mouse models varies greatly, from mildly impaired
Figure 1. Schematic representation of structures and biosynthetic pathways of gangliosides. Major brain gangliosides are shown. Blocks in biosynthesis and enzymes
deﬁcient in two genetically modiﬁed mouse models used in this study are indicated.regeneration of lesioned nerves (St8sia1 null mice), to more severe
manifestations which include demyelination, neurodegeneration,
and motor deﬁcits (B4galnt1 null mice).11,13,14,16,20–22 Even though
the total concentration of gangliosides in the knockout (KO) mice
remains the same as in the wild-type (wt) mice, the ganglioside
composition is markedly changed since the loss of certain ganglio-
side species is compensated by overproduction of other ganglio-
sides. Additional modiﬁcations have been reported for both
ganglioside fractions present in normal ganglioside pattern as well
as for the accumulated gangliosides.19,23,24 O-acetylation of sialic
acid residues is one of the most common covalent modiﬁcations
of gangliosides. Although acetylation is a relatively small structural
change (Fig. 2), it has a considerable impact on physiological prop-
erties of gangliosides. Acetylation of sialic acids has been shown to
serve as a protection against degradation by sialidases, inﬂuence
receptor and pathogen binding, is considered a differentiation mar-
ker during development, and is implicated in tumor progression
and spread.25–30
Even though ganglioside-deﬁcient mice have been used in
research for years, detailed structural analysis of all accumulated
and modiﬁed gangliosides has not yet been fully investigated.
Since acetylation can have a profound impact on ganglioside func-
tions, the aim of this study was to investigate structural composi-
tion and the acetylation patterns of accumulated brain ganglioside
species in two genetically modiﬁed mouse models, St8sia1 null and
B4galnt1 null mice.
2. Results and discussion
2.1. Quantitative and qualitative analysis of native and alkali-
treated ganglioside mixtures isolated from wt, St8sia1 null and
B4galnt1 null mouse brain
The total content of ganglioside-bound sialic acid (GG-SA) in
brain tissue samples of St8sia1 null and B4galnt1 null mice did
not signiﬁcantly differ from wt mice (378 ± 69.12 lg/g and544.03 ± 132.07 lg/g vs 504.44 ± 69.12 lg/g). The obtained values
are in accordance to those previously reported.16,17 HPTLC separa-
tion of individual ganglioside species (Fig. 3) and their relative
quantiﬁcation by ImageJ analysis software conﬁrmed ganglioside
compositional differences typical for analyzed KO mice compared
to wt mice (Table 1).16,17,19 However, comparison of composition
of native and alkali-treated ganglioside mixtures from wt mice
brain tissue indicated presence of additional alkali-labile ganglio-
side fractions (Fig. 3). A fraction which migrates directly above
GT1b fraction could correspond to O-Ac-GQ1b, since the relative
proportion of GQ1b fraction was elevated after the alkaline treat-
ment (Table 1). The second fraction migrates directly below
GD1b fraction, and according to its Rf value it corresponds to pre-
viously reported O-Ac-GT1b.19 The third fraction migrating below
GM1 was recognized as alkali-labile fraction since it completely
disappeared upon alkaline treatment (Fig. 3). The fraction was
attributed as O-Ac-GD1a, based on MS identiﬁcation (Fig. 4,
Table 2). However, the proportion of GD1a did not increase upon
alkaline treatment which is explained by previously observed
HPTLC co-migration of O-Ac-GD1b and GD1a.19 Thus the alkaline
treatment led to slight decrease in GD1a proportion while increase
in GD1b proportion was indeed recorded (Table 1). The fourth alka-
li-labile fraction was noticed within GD3-migrating zone, since the
relative proportion of that zone was considerably reduced after the
alkaline treatment (from 4.1% to <1%, Table 1).
The compositional analysis of St8sia1 nullmice brain ganglioside
mixture by HPTLC showed the presence of three ganglioside
fractions. Two of them, GM1 and GD1a fractions, were expected
considering the GD3 synthase deﬁciency and consequent absence
of b-series gangliosides. The third fraction migrated below GM1
zone and was the only one which disappeared upon the alkaline
treatment (Fig. 3, St8sia1 nullAH). There are no available data on
detailed structural analysis of St8sia1 null mice brain gangliosides,
possiblydue to limited interest becauseof relativelymildphenotype
compared to other ganglioside-deﬁcient mouse models.13,20 How-
ever, investigation of changed acetylation patterns in accumulated
Figure 2. (A) Ganglioside GD1a structure in which the acetylation position is marked with an arrow. (B) Schematic representation of GD1a terminal sialic acid with
acetylation position marked with an arrow (left) and 9-O-acetylated sialic acid (right) conformations. Acetyl group of the outer sialic acid is circled.
Figure 3. HPTLC resorcinol stain of native and alkali-treated brain ganglioside mixtures from wt, St8sia1 null, and B4galnt1 null mice. ‘AH’ subscript denotes alkali-treated
samples. ⁄marks presumed O-Ac-GQ1b.ganglioside species could provide a valuable insight into the proba-
ble compensationmechanismswhich arise from dysfunctional gan-
glioside biosynthesis. Therefore we performed the analysis of this
alkali-labile ganglioside species by mass spectrometry.
The HPTLC analysis of B4galnt1 null mice brain gangliosides
showed three major fractions corresponding to GD3, O-acetylated
GD3, and GM3, in accordance to the GM2/GD2 synthase deﬁciency
and consequent depletion of all complex ganglioside structures.
The O-Ac-GD3 migrating fraction disappeared upon the alkaline
treatment (Fig. 3, B4galnt1 nullAH). The acetylation of GD3, the frac-
tion heavily accumulated in GM2/GD2 synthase-deﬁcient mice,
was previously conﬁrmed by immunohistochemical localizationand mass spectrometry in studies by Matsuda et al.23 and Furuka-
wa et al.24 We did not detect O-Ac-GD3 in wt mouse brain tissue
since it is a very minor ganglioside in the adult brain, while in
developing brain, the expression of O-Ac-GD3 has been associated
to processes such as neurite outgrowth and neuronal migration in
mammalian brain.31–33 Interestingly, it was found that exoge-
nously added GD3 induces its own O-acetylation machinery in
different cell types,34 while other gangliosides fail to induce the
same machinery. This ﬁnding implies that O-acetylation machin-
ery requires very speciﬁc oligosaccharide moieties of gangliosides
and that not all ganglioside species are susceptible to O-acetylation
in the same proportion.
Figure 4. Mass spectra of native ganglioside mixtures from wt, St8sia1 null, and B4galnt1 null mouse brain samples.
Table 1
Relative proportions of individual ganglioside species present in total native and alkali-treated ganglioside mixtures isolated from wild-type, St8sia1
null, and B4galnt1 null mouse brain tissue
Ganglioside Proportion of individual ganglioside (%)
wt wtAH St8sia1 null St8sia1 nullAH B4galnt1 null B4galnt1 nullAH
GM3 <1 <1 2.2 2.2 28.2 28.5
GM2 <1 <1 1.6 1.5 — —
O-Ac-GD3 — — — — 16 —
GM1 19.9 18.6 20.6 20.1 — —
O-Ac-GD1a <1 — 4.9 — — —
GD3 4.1 <1 — — 55.8 71.5
GD1a/(O-Ac-GD1b) 44.1 42.4 70.7 76.2 — —
GD2/GT3 4.3 5 — — — —
GD1b 8.1 9.2 — — — —
O-Ac-GT1b 2.2 — — — — —
O-Ac-GQ1b⁄ <1 — — — — —
GT1b 13.2 19.5 — — — —
GQ1b 1.3 3.7 — — — —
wt, wild-type; ‘AH’ subscript denotes alkali-treated samples; —, not detected; ⁄presumed O-Ac-GQ1b.2.2. Mass spectrometric analysis of native ganglioside mixtures
isolated from wt, St8sia1 null and B4galnt1 null mouse brain
tissue
The puriﬁed native ganglioside mixtures isolated from wt,
St8sia1 null and B4galnt1 null mice brains were directly screened
by electrospray ionization mass spectrometry (ESI MS). The ob-
tained spectra (MS1) are presented in Figure 4, and mass region
containing the ions with lower abundance is shown in Supplemen-
tary Figure 1. A complex molecular ion pattern was detected, con-
ﬁrming corresponding chromatographically visualized ganglioside
patterns. All major individual ganglioside fractions showed high
diversity in their ceramide portions. The only species that was be-
yond the detection limit was GQ1b. Detected molecular ions and
their corresponding proposed ganglioside structures are presented
in Table 2.
The spectrum of wt mice brain ganglioside mixture was the
most complex of the analyzed samples showing all of the ganglio-
side species typically present in mice brain.In the spectrum of St8sia1 null mice brain ganglioside mixture,
the ions corresponding to GD3 gangliosides are missing. The most
abundant signals in MS scans are those corresponding to GD1 and
GM1 species which is in accordance to HPTLC data. The ions corre-
sponding to GT1 (d18:1/18:0) and GT1 (18:1/20:0) (doubly
charged ion atm/z 1077.02) ganglioside species were also detected
although GT1 fraction was not observed on HPTLC due to its much
lower sensitivity, as well as rather low amount of ganglioside
mixture applied to the plate. GT1 ganglioside species were further
subjected to structural analysis by MS/MS sequencing in the nega-
tive ion mode. The product ion spectrum of the doubly charged
molecular ion at m/z 1063.00, corresponding to GT1 (d18:1/18:0)
is shown in Figure 5. The spectrum conﬁrms the presence of
trisialylated tetraose structure which may be attributed to GT1a
isomer since the biosynthetic pathway of b- and c-series ganglio-
sides is blocked in this KO model.
B4galnt1 nullmouse brain ganglioside mixture spectrum (Fig. 4)
shows abundant ions that correspond to GM3, O-acetyl-GM3, GD3,
and O-acetyl-GD3 species. These species accumulated in B4galnt1
Table 2
The most abundant ganglioside molecular ions detected by mass spectrometric
screening of native ganglioside mixtures isolated from brain tissue of wild-type,
St8sia1null, and B4galnt1 null mice, and their corresponding proposed ganglioside
structures
m/z Molecular ion Proposed structure WT St B4
1179.75 [MH] GM3 (d18:1/18:0) + + +
1193.72 [MH] GM3 (d18:1/19:0) +
1207.76 [MH] GM3 (d18:1/20:0) + +
1221.75 [MH] O-Ac-GM3 (d18:1/18:0) + +
1235.75 [MH] GM3 (d18:1/22:0) +
1257.88 [M+Na2H] +
1261.71 [MH] GM3 (d18:1/24:1) +
1299.68 [M+Na2H] O-Ac-GM3 (d18:1/22:0) +
734.89 [MH] GD3 (d18:1/18:0) +
1470.81 [MH] + +
1484.79 [MH] GD3 (d18:1/19:0) +
748.89 [M2H]2 GD3 (d18:1/20:0) +
1498.82 [MH] +
755.88 [M2H]2 O-Ac-GD3 (d18:1/18:0) +
1512.77 [MH] +
769.90 [M2H]2 O-Ac-GD3 (d18:1/20:0) +
1540.83 [MH] +
1516.99 [MH] GM1 (d18:1/16:0) + +
1544.82 [MH] GM1 (d18:1/18:0) + +
1572.98 [MH] GM1 (d18:1/20:0) + +
917.48 [M2H]2 GD1 (d18:1/18:0) + +
1835.96 [MH] + +
1858.28 [M+Na2H] + +
931.51 [M2H]2 GD1 (d18:1/20:0) + +
1885.96 [M+Na2H] + +
938.45 [M2H]2 O-Ac-GD1 (d18:1/18:0) + +
1877.91 [MH] + +
945.48 [M2H]2 GD1 (d18:1/22:0) + +
952.47 [M2H]2 O-Ac-GD1 (d18:1/20:0) + +
958.46 [M2H]2 GD1 (d18:1/24:1) + +
980.44 [M2H]2 O-Ac-GD1 (d18:1/24:0) + +
1062.98 [M2H]2 GT1 (d18:1/18:0) +
1071.07 [M2H]2 O-Ac-GT1 (d18:1/16:0) +
1077.02 [M2H]2 GT1 (d18:1/20:0) + +
1083.98 [M2H]2 O-Ac-GT1 (d18:1/18:0) + +
1098.02 [M2H]2 O-Ac-GT1 (d18:1/20:0) +
Data on the most abundant ions are given, in accordance to MS scan presented in
Figure 4.nullmice are present in minor to neglectable quantities in wt mice.
All four ganglioside fractions from B4galnt1 null brain tissue
showed high diversity of ganglioside species regarding the struc-
ture of ceramide portion (Supplementary Table 1). O-acetylated
GM3 species was not previously reported in a murine model with
disrupted ganglioside biosynthesis.Figure 5. The product ion spectrum of the doubly charged molec2.3. Mass spectrometric analysis of preparatively isolated GD1a-
migrating fractions from wt and St8sia1 null mouse brain
ganglioside mixtures
Gangliosides of b-series are absent in St8sia1 null mice brain
while GM1 and GD1a gangliosides accumulate.13,20 In order to
compare the GD1a composition of St8sia1 null versus wt mice
brain, both HPTLC GD1a-migrating fractions were isolated and
analyzed by MS. The MS screening revealed numerous signals in
GD1a-migrating fractions of both samples (Fig. 6). Keeping in mind
that O-acetylated GD1b species co-migrate with GD1a species,19 it
is likely that O-acetylated GD1b species were present in wt mice
GD1a-migrating fraction, while in St8sia1 null mice brain only
GD1a species were present in the analyzed fraction. The GD1a-
migrating fraction total ion intensity was higher in St8sia1 null than
in wt mice brain, which is in accordance with the accumulation of
GD1a species due to GD3 synthase deﬁciency in St8sia1 null mice.
Since the m/z values of some O-Ac-GD1b and GD1a gangliosides
are very close (doubly charged ions at m/z 938.48 for O-Ac-GD1
(d18:1/18:0), 938.50 for GD1 (d18:1/21:0) and 939.48 for GD1
(t18:1/20:0)), we suppose that more than one ion was present
within the same peak. Higher abundance of O-acetylated GD1a
species was detected by MS1 in St8sia1 null vs. wt mice brain, as
observed by HPTLC analysis. Interestingly, a higher abundance of
O-acetylated GD1 (GD1b) has been reported for St3gal2/3 double
null mice.19 It seems that total acetylation of gangliosides is main-
tained in both wt and KO murine brain tissue, e.g. observed
increased proportions of acetylated ganglioside species in de-
scribed KO-models were a consequence of different distribution
of acetylation, depending on the type of block in ganglioside bio-
synthesis. Speciﬁc effects, interactions, and physiological roles of
(accumulated) acetylated gangliosides have yet to be explored.
2.4. Mass spectrometric and tandem mass spectrometric
analysis of preparatively isolated ganglioside fraction from
St8sia1 null mouse brain containing GM1 and O-Ac-GD1a
The two ganglioside fractions from St8sia1 null mice brain
observed on HPTLC migrating as GM1 standard and presumed
O-Ac-GD1a (Fig. 3) were scrapped from the plate and preparatively
isolated in order to perform more detailed structural analysis. Fig-
ure 7 represents the spectrum of that fraction obtained by MS1
screening; the molecular ions corresponding to GM1 and O-Ac-
GD1 species are also represented. MS analysis revealed several ions
corresponding to GM1 ganglioside species with different ceramide
moieties, together with signals that correspond to O-acetylatedular ion at m/z 1063.00, corresponding to GT1a (d18:1/18:0).
Figure 7. The MS1 screening of preparatively isolated ganglioside fraction containing GM1 and O-Ac-GD1a species from St8sia1 null mouse brain samples. The fraction was
scrapped off the HPTLC plate and extracted from silica gel.
Figure 6. Mass spectra of preparatively isolated GD1a-migrating fractions from (A) wt and (B) St8sia1 null mouse brain samples. The fractions were scrapped off the HPTLC
plate and extracted from silica gel.GD1 species. The doubly charged ion at m/z 938.95 corresponding
to O-Ac-GD1 (d18:1/18:0) was subjected to tandem MS, and its
product ion spectrum is presented in Figure 8. The major fragment
ion relevant for deducing the presence of O-acetylation in the
O-Ac-GD1 structure was detected at m/z 1586.9 attributed to the
sequence O-Ac-NeuAc-Gg4Cer (Fig. 8) which is exactly for
Dm = 291 lower than the theoretical m/z of the singly charged
molecular ion corresponding to O-Ac-GD1 (d18:1/18:0), therefore
indicating release of one NeuAc residue from the molecular ion,
while O-Ac-NeuAc residue is still present within the fragment at
m/z 1586.9. The ion at m/z 1544.92 is for Dm = 42 lower than the
ion at m/z 1586.9, that conﬁrms the release of the O-Ac residue.
The other detected fragment ions, structurally deﬁned in Figure 8,
conﬁrm the structure of O-Ac-GD1. Due to block in b-series gangli-
oside synthesis in this KO model, the presence of b-series isomercan be excluded, which is additionally supported by the absence
of fragment ions at m/z 599 and 581 that would indicate the disi-
alo-residue (Fig. 8). Therefore we can conclude that the ion at m/z
938.95 corresponds to O-acetylated GD1a with d18:1/18:0
ceramide. The analogous fragmentation pattern was obtained by
tandem MS of the ion at m/z 952.92 that corresponds to
O-Ac-GD1a (d18:1/20:2).
3. Conclusions
Brain gangliosides derived from mice with changed ganglioside
composition and wild-type mice were characterized by means of
HPTLC and mass spectrometry. Observed high structural complex-
ity of ganglioside pattern was additionally diversiﬁed by sialic acid
O-acetylation. The O-acetylated GD1a and O-acetylated GM3
Figure 8. The product ion spectrum of the doubly charged molecular ion at m/z 938.95 corresponding to O-Ac-GD1a (d18:1/18:0).species, not previously reported in a murine model with disrupted
ganglioside biosynthesis, were identiﬁed. Additionally, detailed
mass spectrometric structural analysis of brain ganglioside compo-
sition in St8sia1 null mice was provided. Our ﬁndings in mice with
altered ganglioside biosynthesis indicate that the diversity of gan-
glioside structures, as well as acetylation patterns, is even higher
than previously reported. These ﬁndings entail further investiga-
tion of newly detected O-acetylated structures, particularly their
cellular localization and involvement in neurodevelopmental
processes.
4. Experimental
4.1. Mouse models with altered ganglioside biosynthesis
Two genetically modiﬁed mouse models were used and com-
pared to wt mice. Mice with disrupted St8sia1 gene (St8sia1 null)
coding for a-N-acetylneuraminate a-2,8-sialyltransferase (GD3
synthase; EC 2.4.99.8) accumulate a-series gangliosides (GM1,
GM2, GM3, GD1a) while they are depleted of both b- and c-series
gangliosides (GD3, GD1b, GT1b, GT3, GT2, GT1c)13,20 (Fig. 1). Mice
with a disrupted B4galnt1 gene (B4galnt1null mice) which lack the
enzyme GM2/GD2 synthase (UDP-N-acetyl-D-galactosamine:GM3/
GD3 N-acetyl-D- galactosaminyltransferase, EC 2.4.1.92) conse-
quently do not synthesize the major gangliosides common to ver-
tebrate brain but instead synthesize comparable amounts of
simple gangliosides GM3 and GD311,21,22 (Fig. 1).
Adult St8sia1 null and B4galnt1 nullmice were compared to age-
and sex-matched wild-type littermates with the same genetic
background (C57BL/6). Founder St8sia1 null and B4galnt1 null mice
(C57BL/6 background) originated from The Scripps Research Insti-
tute, La Jolla, California, as a part of the Consortium for Functional
Glycomics. Sixteen mice were used in this study. Animals were
kept in the same facility under same conditions in all aspects. All
experimental procedures were approved by regional ethics
committees for scientiﬁc experiments, and ethical guidelines were
followed, in accordance with institutional and government
guidelines.
4.2. Ganglioside extraction and puriﬁcation
Mice were anesthetized with isoﬂuorane and sacriﬁced. Brains
were rapidly removed and dissected in a standardized manner.
Frontal cortex tissue was weighed prior to ganglioside extraction
procedure which was performed according to the method of Sven-
nerholm and Fredman,35 as modiﬁed in our laboratory.36 Brieﬂy,
tissue samples were homogenized in ice-cold distilled water (W)in a Potter–Elvehjem glass-Teﬂon homogenizer to obtain 10%
homogenate. Lipids were extracted twice using solvent mixture
of chloroform (C):methanol (M) (1:2, by vol.), followed by partition
and repartition by adding M and W to a ﬁnal volume ratio 1:1:0.7.
Upper phases were collected and evaporated to dryness. Dried gan-
glioside extracts were dissolved in C/M/W (60:30:4.5, by vol.) and
left for 12 h at +4 C in order to induce precipitation of residual
proteins. The precipitate was removed by centrifugation. The gan-
glioside extract was evaporated and the residue dissolved in C/M/
W (60:30:4.5, by vol.) and puriﬁed by gel ﬁltration on Sephadex-
G25 Fine gel (Sigma–Aldrich). The collected eluate was evaporated
and puriﬁed ganglioside extracts were used for quantitative and
qualitative analysis.
4.3. Quantitative analysis of gangliosides
Quantitative analysis of total ganglioside content was
performed according to the spectrophotometric method of Sven-
nerholm,37 as modiﬁed by Miettinen and Takki-Luukkainen.38
The absorbances of samples and N-acetylneuraminic acid (Sig-
ma–Aldrich) used as a standard in a range of known concentrations
were determined at 580 nm. The contents of ganglioside-bound
sialic acid (GG–SA) were expressed as microgram GG–SA per gram
of fresh tissue w.w.
4.4. Qualitative analysis of native ganglioside mixtures and
alkali-labile ganglioside species
Qualitative analysis was performed by high performance thin
layer chromatography (HPTLC) separation of individual ganglioside
species on silica gel plate (Merck). HPTLC was used for three
purposes: (1) collection of compositional data following resor-
cinol–HCl staining of separated ganglioside patterns, (2) investiga-
tion of alkali-labile ganglioside species and (3) preparative
isolation of separated fractions for subsequent mass spectrometry
(MS) analysis. In all cases plates were developed in a solvent sys-
tem containing C, M, and 12 mM aq CaCl2 (50:40:10, by vol.). The
mixture of gangliosides from bovine brain (Cronassial, Fidia
Research Laboratories) was used as a reference.
For qualitative analysis of native ganglioside mixtures the sam-
ples of puriﬁed ganglioside extracts were dissolved in an adequate
volume of C:M:W (60:30:4.5, by vol.) and the aliquots correspond-
ing to ganglioside content in 10 mg of analyzed brain sample were
spotted to the HPTLC plate. Resolved gangliosides were detected by
resorcinol–HCl reagent.37 Images of the developed, stained plates
were scanned and analyzed using ImageJ analysis software (NIH)
enabling relative quantiﬁcation of individual ganglioside species,
expressed as their relative proportions (%) in total ganglioside con-
tent in the analyzed sample.
To check the presence of alkali-labile ganglioside species in
puriﬁed ganglioside mixtures, alkaline treatment was performed
according to the procedure of Sonnino et al.39 Brieﬂy, dried aliquots
corresponding to ganglioside content in 10 mg of analyzed brain
sample were dissolved in 100 lL of 17 M ammonia and incubated
at room temperature overnight. After complete evaporation of
ammonia, the sample was monitored by HPTLC as described above.
For preparative isolation of individually separated ganglioside
fractions, native puriﬁed ganglioside mixtures were dissolved in
an adequate volume of C:M:W (60:30:4.5, by vol.) and aliquots
containing 15 lg of GG–SA were spotted to the HPTLC plate. The
plate was developed, dried, and the separated ganglioside fractions
were visualized by iodine vapors. Ganglioside spots were marked
with a pencil. After desorption of iodine, the marked areas were
scrapped off the plate and the ganglioside fractions were extracted
from silica gel in C:M:W (60:30:4.5, by vol.), ﬁltrated on Celite
(Serva) and evaporated for subsequent direct MS analysis.
4.5. Mass spectrometry analysis
MS and tandem MS experiments were performed on a Bruker
amaZon ETD ion trap system (Bruker Daltonik GmbH, Germany)
equipped with Apollo electrospray ionization source. The solutions
of the native ganglioside mixtures were prepared by dissolving
dried ganglioside extracts in methanol at concentrations of
1.6 lM GG–SA. The individual ganglioside fractions preparatively
isolated from HPTLC plates were also dissolved in methanol. All
samples were introduced into the electrospray ionization source
by direct infusion at a ﬂow rate of 65 ll/h. The capillary voltage
was set as 4500 V while high voltage end plate offset was
500 V. The temperature and ﬂow rate of the drying gas were
set at 210 C and 5 L/min, respectively. Helium was used as the col-
lision gas. The CID excitation time was 40 ms and the amplitude
was in the 0.4–1 V range. All spectra were acquired in negative
ion mode using a scan range from 280 to 3000 m/z. DataAnalysis
software 4.0 (Bruker Daltonik GmbH, Germany) was used for anal-
ysis (charge deconvolution and data reduction) and extraction of
the MS and MS/MS data. Ganglioside ion identiﬁcation was accom-
plished using our own software application ‘GSL ﬁnder’ and its
accompanying ganglioside database.
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